Winslow Evans & Crocker Inc. Acquires 162 Shares of Amgen, Inc. (AMGN)

Share on StockTwits

Winslow Evans & Crocker Inc. grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,256 shares of the medical research company’s stock after buying an additional 162 shares during the period. Winslow Evans & Crocker Inc.’s holdings in Amgen were worth $1,190,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of AMGN. BKD Wealth Advisors LLC lifted its holdings in shares of Amgen by 3.9% in the fourth quarter. BKD Wealth Advisors LLC now owns 4,032 shares of the medical research company’s stock valued at $785,000 after purchasing an additional 150 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Amgen by 2.2% in the fourth quarter. Quadrant Capital Group LLC now owns 3,958 shares of the medical research company’s stock valued at $749,000 after purchasing an additional 85 shares in the last quarter. Advisors Capital Management LLC lifted its holdings in shares of Amgen by 65.1% in the fourth quarter. Advisors Capital Management LLC now owns 8,152 shares of the medical research company’s stock valued at $1,587,000 after purchasing an additional 3,214 shares in the last quarter. Appleton Partners Inc. MA lifted its holdings in shares of Amgen by 15.0% in the fourth quarter. Appleton Partners Inc. MA now owns 23,987 shares of the medical research company’s stock valued at $4,670,000 after purchasing an additional 3,127 shares in the last quarter. Finally, Joel Isaacson & Co. LLC lifted its holdings in shares of Amgen by 3.3% in the fourth quarter. Joel Isaacson & Co. LLC now owns 3,432 shares of the medical research company’s stock valued at $688,000 after purchasing an additional 111 shares in the last quarter. 78.01% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on AMGN. Mizuho set a $208.00 price target on Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Royal Bank of Canada restated a “neutral” rating and issued a $192.00 price target on shares of Amgen in a report on Tuesday. Citigroup upgraded Amgen from a “neutral” rating to a “buy” rating and cut their price target for the company from $211.00 to $205.00 in a report on Wednesday. Credit Suisse Group began coverage on Amgen in a report on Monday, May 20th. They issued an “outperform” rating and a $208.00 price target on the stock. Finally, BidaskClub lowered Amgen from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $209.05.

AMGN traded down $0.83 on Friday, hitting $171.28. 2,415,129 shares of the company were exchanged, compared to its average volume of 3,015,929. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $210.19. The firm has a market capitalization of $104.47 billion, a PE ratio of 11.89, a PEG ratio of 2.24 and a beta of 1.15. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The business had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the prior year, the company posted $3.47 earnings per share. Amgen’s revenue was up .1% on a year-over-year basis. On average, research analysts forecast that Amgen, Inc. will post 13.94 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.39%. Amgen’s payout ratio is presently 40.28%.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total transaction of $351,460.00. Following the sale, the director now owns 15,092 shares in the company, valued at $2,652,117.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 6,000 shares of company stock worth $1,115,580 in the last quarter. 0.25% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Winslow Evans & Crocker Inc. Acquires 162 Shares of Amgen, Inc. (AMGN)” was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2019/05/25/winslow-evans-crocker-inc-acquires-162-shares-of-amgen-inc-amgn/3413048.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Overbought

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.